Latest Strategy News

Elixir Energy is set to resume production testing at its Diona-1 well this quarter and prepare for the high-impact Lorelle-3 appraisal well drilling in January 2026, aiming to unlock significant gas resources in Queensland’s Taroom Trough.

Scorpion Minerals Limited has resumed trading following a pivotal announcement on drilling results, a new tenement application, and a potential strategic partnership, alongside financing updates.

Greenvale Energy’s recent spectral gamma logging at the Oasis Uranium Project reveals significant high-grade uranium extensions, reinforcing the deposit’s scale potential and prompting a new trenching program.

Associate Global Partners Limited reported a 4.6% increase in funds under management to $1.464 billion for Q3 2025, driven by robust inflows and standout returns from its WCM strategies. The company also sustained positive operating cash flows for the fourth consecutive quarter.

Arika Resources reports significant high-grade gold mineralisation from maiden drilling at new geophysical targets south of Pennyweight Point, validating its exploration strategy at the Yundamindra Gold Project.

Omnia Metals Group has successfully issued 54 million shares, raising $1.08 million as part of a broader $1.58 million placement. The company now looks to shareholders for approval to complete the remaining share and option issues.

Whitebark Energy’s fresh petrophysical analysis reveals significant dry gas zones in its Warro Gas Field, boosting its commercial prospects and prompting a $750,000 capital raise to fast-track development.

Centuria Industrial REIT has secured a landmark 10-year lease with Tesla, delivering a 133% re-leasing spread and deferring redevelopment plans, while pursuing a major data centre expansion in Victoria.

Smart Parking Limited reports a record FY25 with revenues up 42% to $77.2 million, driven by organic growth and strategic acquisitions including Peak Parking in the US. The company targets 3,000 managed sites by 2028, leveraging proprietary AI technology across multiple international markets.

CVC Limited is contemplating a fresh offer of Capital Notes, potentially including a reinvestment option for existing holders, contingent on market and regulatory conditions.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.